In the 2018 EASL clinical practice guidelines, AFP can be used as an indicator for the diagnosis and prognosis of advanced HCC (6), and high serum AFP may indicate drug resistance and a poor prognosis in many HCC patients (3–6). The gene discussed is AFP; the disease is hepatocellular carcinoma.